Net margin is calculated as Net Income divided by its Revenue. Oncoinvent ASA's Net Income for the
six
months ended in Dec. 2025 was kr-103.09 Mil. Oncoinvent ASA's Revenue for the
six
months ended in Dec. 2025 was kr11.35 Mil. Therefore, Oncoinvent ASA's net margin for the quarter that ended in Dec. 2025 was -908.49%.
The historical rank and industry rank for Oncoinvent ASA's Net Margin % or its related term are showing as below:
CHIX:ONCINo'
s Net Margin % Range Over the Past 10 Years
Min: -77666.32 Med: -24090.69 Max: -673.13
Current: -978.32
CHIX:ONCINo's Net Margin % is ranked worse than 78.65% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs CHIX:ONCINo: -978.32
Oncoinvent ASA (CHIX:ONCINo) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Oncoinvent ASA Net Margin % Related Terms
Oncoinvent ASA Net Margin % Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Net Margin % of -908.49% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #744 out of 946 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Oncoinvent ASA's Net Margin % too high?
Oncoinvent ASA's current Net Margin % is -908.49%. Based on the distribution chart, Oncoinvent ASA ranks #744 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #744 out of 946 companies for Net Margin %. This places Oncoinvent ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Net Margin % is -908.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Net Margin % of -908.49%. The stock's GF Value™ is kr20,399.27, compared to a current price of kr1,039.91 — trading 94.9% below its estimated fair value. The current Net Margin % is -908.49%. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Net Margin % is -908.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.9% below its estimated GF Value™ of kr20,399.27.
Key valuation signals for CHIX:ONCINO:
Net Margin %: -908.49%
GF Value™: kr20,399.27 vs. price of kr1,039.91 (94.9% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
